scholarly journals RNAi-Induced Immunity

10.5772/61632 ◽  
2016 ◽  
Author(s):  
Wenyi Gu
Keyword(s):  
Induced Immunity

Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling

2020 ◽  
Vol 21 (5) ◽  
pp. 546-554 ◽  
Author(s):  
Chuanhui Han ◽  
Zhida Liu ◽  
Yunjia Zhang ◽  
Aijun Shen ◽  
Chunbo Dong ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Caspase 9 ◽  
Radiation Induced ◽  
Induced Immunity

scholarly journals Cord Blood-Based Approach to Assess Candidate Vaccine Adjuvants Designed for Neonates and Infants

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 95
Author(s):  
Daisuke Tokuhara ◽  
Norikatsu Hikita
Keyword(s):  
Cord Blood ◽  
Protective Immunity ◽  
Current Knowledge ◽  
Current System ◽  
Innate Immune ◽  
Vaccine Adjuvants ◽  
Adult Humans ◽  
Neonates And Infants ◽  
Induced Immunity ◽  
Review Current

Neonates and infants are particularly susceptible to infections, for which outcomes tend to be severe. Vaccination is a key strategy for preventing infectious diseases, but the protective immunity achieved through vaccination typically is weaker in infants than in healthy adults. One possible explanation for the poor acquisition of vaccine-induced immunity in infants is that their innate immune response, represented by toll-like receptors, is immature. The current system for developing pediatric vaccines relies on the confirmation of their safety and effectiveness in studies involving the use of mature animals or adult humans. However, creating vaccines for neonates and infants requires an understanding of their uniquely immature innate immunity. Here we review current knowledge regarding the innate immune system of neonates and infants and challenges in developing vaccine adjuvants for those children through analyses of cord blood.

scholarly journals P18-11. DALIA: dendritic cell and lipopeptide-induced immunity against AIDS: a phase I trial

Retrovirology ◽  
2009 ◽  
Vol 6 (Suppl 3) ◽  
pp. P320
Author(s):  
J Banchereau ◽  
C Harrod ◽  
A Cobb ◽  
G Chene ◽  
L Sloan ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Phase I ◽  
Phase I Trial ◽  
Induced Immunity

scholarly journals Association between season of vaccination and antibody levels against infectious diseases

2020 ◽  
Vol 148 ◽  
Author(s):  
T. C. Abreu ◽  
H. Boshuizen ◽  
L. Mollema ◽  
G. A. M. Berbers ◽  
H. Korthals Altes
Keyword(s):  
Disease Burden ◽  
Seasonal Cycles ◽  
Inclusion Criteria ◽  
Cross Sectional ◽  
Vaccine Preventable Diseases ◽  
Multivariable Regression ◽  
Immunological Protection ◽  
Antibody Levels ◽  
Induced Immunity ◽  
Tetanus Antibodies

Abstract Vaccination has reduced the disease burden of vaccine-preventable diseases. However, the extent to which seasonal cycles of immunity could influence vaccine-induced immunity is not well understood. A national cross-sectional serosurveillance study performed in the Netherlands (Pienter-2) yielded data to investigate whether season of vaccination was associated with antibody responses induced by DT-IPV (diphtheria, tetanus and poliomyelitis), MMR (measles, mumps and rubella) and meningococcus C (MenC) vaccines in children. In total, 434 children met the inclusion criteria to study DT-IPV immunity, 811 for MMR and 311 for MenC. Differences in log(antibody levels) by season of vaccination were investigated with linear multivariable regression analyses. Seroconversion rates varied according to season of vaccination for rubella (90% of autumn-vaccinated children vs. 99% of winter-vaccinated had concentrations above cut-off levels). Summer-vaccinated boys showed a slower decline of tetanus antibodies (6% per month), in comparison with winter-vaccinated boys. In conclusion, season of vaccination showed little association with immunological protection. However, a number of associations were seen with a P-value of about 0.03; and adding data from a just-completed nationwide serological study might add more power to the current study. Further immunological and longitudinal investigations could help understand the mechanisms of seasonal influence in vaccine-induced responses.

scholarly journals COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses

2021 ◽  
pp. 108614
Author(s):  
Manuel Adrian Acuña-Zegarra ◽  
Saúl Díaz-Infante ◽  
David Baca-Carrasco ◽  
Daniel Olmos Liceaga
Keyword(s):  
Induced Immunity ◽  
Modeling Study

scholarly journals Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs

2019 ◽  
Vol 93 (21) ◽  
Author(s):  
Santosh Dhakal ◽  
Sabra L. Klein
Keyword(s):  
Influenza Virus ◽  
Influenza Vaccine ◽  
Virus Vaccine ◽  
Vaccine Efficacy ◽  
Public Health Problem ◽  
Influenza Virus Vaccine ◽  
Host Factors ◽  
Influenza Vaccines ◽  
Vaccine Type ◽  
Induced Immunity

ABSTRACT Influenza is a global public health problem. Current seasonal influenza vaccines have highly variable efficacy, and thus attempts to develop broadly protective universal influenza vaccines with durable protection are under way. While much attention is given to the virus-related factors contributing to inconsistent vaccine responses, host-associated factors are often neglected. Growing evidences suggest that host factors including age, biological sex, pregnancy, and immune history play important roles as modifiers of influenza virus vaccine efficacy. We hypothesize that host genetics, the hormonal milieu, and gut microbiota contribute to host-related differences in influenza virus vaccine efficacy. This review highlights the current insights and future perspectives into host-specific factors that impact influenza vaccine-induced immunity and protection. Consideration of the host factors that affect influenza vaccine-induced immunity might improve influenza vaccines by providing empirical evidence for optimizing or even personalizing vaccine type, dose, and use of adjuvants for current seasonal and future universal influenza vaccines.

scholarly journals HIV Universal Vaccine

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Marek Malecki ◽  
Bianka Saetre
Keyword(s):  
Viral Infections ◽  
Natural Infection ◽  
High Specificity ◽  
Molecular Medicine ◽  
High Efficacy ◽  
Therapeutic Vaccines ◽  
Rapid Reduction ◽  
Universal Vaccine ◽  
Healthy Donors ◽  
Induced Immunity

Background: For many deadly viruses, there are no preventive and / or therapeutic vaccines approved by health authorities World-wide (e.g., HIV, Ebola, Dengue, and many others). Although, for some viruses, prophylactic vaccines are very effective (e.g., HBV, Polio, Rota, and many others). In this realm, we design, manufacture, test, and streamline into the clinics novel viral universal vaccines (VUV). VUV have such unique features, that medical vaccination or natural infection induced immunity against some viruses (e.g., HBV) in patients, who became infected with other viruses (e.g., HIV), upon the VUV’s administration, is redirected against these other, newly infecting viruses (e.g., HIV). Specific Aim: The specific aim of this work was biomolecular engineering of the HIV universal vaccine (HIVUV) comprising the two main functional domains: CD4 or anti-gp120 - as the HIV tagging domain and HBsAg - as the immune response eliciting domain, so that upon its administration the HBV medical immunization or natural infection induced immunity would be redirected, accelerated, and amplified to fight the HIV infection. Healthy Donors and Patients: Per the Institutional Review Board approval and in compliance with the Declaration of Helsinki, all healthy donors and patients were presented with the Patients’ Bill of Rights and provided Patient Informed Consent. All the procedures were pursued by the licensed medical doctors. Methods & Results: We have biomolecularly engineered HIV universal vaccine (HIVUV) comprising human CD4 or anti-gp120 and HBsAg of HBV. By immunoblotting and magnetic activated molecular sorting, we have demonstrated high specificity of this vaccine in binding HIV. By flow cytometry and nuclear magnetic resonance, we have demonstrated high efficacy of these vaccines to engage HBV immunized patients’ immune system to work against HIV. Administration of HIVUV to blood or lymph of the HIV+ patients resulted in rapid reduction of the HIV viremia down to undetectable. It also resulted in protection of populations of CD4+ cells against HIV caused decline. Conclusions: We have demonstrated the proof of concept for high efficacy of VUV, specifically HIVUV, in annihilating HIV. Nevertheless, the same compositions, processes, and methods, for persons skilled in biotechnology, pharmacogenomics, and molecular medicine, are adaptable for other deadly viral infections, which we vigorously pursue.

Sign in / Sign up

Export Citation Format

Share Document